Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399508 | 0.91 | KMT2A (0.41) | MEN1KMT2AP2RX7PDE10APOLB | |
| SCHEMBL16627462 | 0.89 | KMT2A (0.43) | MEN1KMT2AP2RX7PDE10APOLB | |
| SCHEMBL8372089 | 0.88 | PDE10A (0.39) | MEN1KMT2APDE10ANPC1RAB9A | |
| SCHEMBL16627449 | 0.87 | MEN1 (0.43) | MEN1KMT2AP2RX7PDE10APOLB | |
| SCHEMBL518962 | 0.87 | PDE10A (0.39) | MEN1KMT2APDE10ANPC1RAB9A | |
| SCHEMBL16625711 | 0.85 | L3MBTL1 (0.41) | MEN1KMT2AL3MBTL1CCR1CCR2 | |
| SCHEMBL519478 | 0.84 | PDE10A (0.54) | MEN1KMT2APDE10ANPC1RAB9A | |
| SCHEMBL15195491 | 0.83 | PDE10A (0.37) | MEN1KMT2AP2RX7PDE10ANPC1 | |
| SCHEMBL518809 | 0.83 | P2RX7 (0.41) | P2RX7PDE10A | |
| SCHEMBL519254 | 0.82 | PDE10A (0.47) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | MEN1 3211/4885KMT2A 1900/4885P2RX7 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.